Epigenetic Therapy of Cancer: Past, Present and Future

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2006 Feb 18

PMID 16485345

Citations 466

Authors

Christine B Yoo

Peter A Jones

Affiliations

Soon will be listed here.

Abstract

The initiation and progression of cancer is controlled by both genetic and epigenetic events. Unlike genetic alterations, which are almost impossible to reverse, epigenetic aberrations are potentially reversible, allowing the malignant cell population to revert to a more normal state. With the advent of numerous drugs that target specific enzymes involved in the epigenetic regulation of gene expression, the utilization of epigenetic targets is emerging as an effective and valuable approach to chemotherapy as well as chemoprevention of cancer.

Citing Articles

Anticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications.

Ibrahim S, Khan M, Khurram I, Ghani M, Sharifi-Rad J, Calina D Eur J Med Res. 2025; 30(1):169.

PMID: 40082963 PMC: 11907871. DOI: 10.1186/s40001-025-02401-0.

Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs.

Castillo-Aguilera O, Depreux P, Halby L, Bailly C, Dominguez-Ramirez L, Gul S RSC Med Chem. 2025; .

PMID: 40061000 PMC: 11886420. DOI: 10.1039/d4md00899e.

Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition.

Jakobsen M, Traynor S, Nielsen A, Dahl C, Staehr M, Jakobsen S J Exp Clin Cancer Res. 2025; 44(1):21.

PMID: 39844304 PMC: 11755921. DOI: 10.1186/s13046-025-03294-x.

Quinoline-based compounds can inhibit diverse enzymes that act on DNA.

Zhou J, Chen Q, Ren R, Yang J, Liu B, Horton J Cell Chem Biol. 2024; 31(12):2112-2127.e6.

PMID: 39437789 PMC: 11663113. DOI: 10.1016/j.chembiol.2024.09.007.

Research hotspots and trends of epigenetic therapy in oncology: a bibliometric analysis from 2004 to 2023.

Li S, Liang X, Shao Q, Wang G, Huang Y, Wen P Front Pharmacol. 2024; 15:1465954.

PMID: 39329125 PMC: 11424529. DOI: 10.3389/fphar.2024.1465954.